• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by AN2 Therapeutics Inc.

    8/14/24 9:00:08 PM ET
    $ANTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ANTX alert in real time by email
    SC 13G/A 1 antx13g.htm

    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549

    SCHEDULE 13G/A*
    (Rule 13d-102)

    INFORMATION TO BE INCLUDED
    IN STATEMENTS FILED PURSUANT
    TO RULES 13d-1(b), (c), AND
    (d) AND AMENDMENTS THERETO
    FILED PURSUANT TO RULE 13d-2
    (AMENDMENT NO.  1  )*

    AN2 Therapeutics, Inc.
    (Name of Issuer)
     
     Common Stock, $0.00001 par value per share
    (Title of Class of Securities)
     
     037326105
    (CUSIP Number)
     
     August 14, 2024
    (Date of Event Which Requires Filing of this Statement)
     
    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)
    ☒ Rule 13d-1(c)
    ☐ Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
     

     

     
    1
    NAMES OF REPORTING PERSONS
     
     
     BML Investment Partners, L.P.
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
       
    (a)☐
       
    (b)☒
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
     Delaware
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
     
     
     0
     
     
     
     
    6
    SHARED VOTING POWER
     
     
    5,749,432
     
     
     
     
    7
    SOLE DISPOSITIVE POWER
     
     
     0
     
     
     
     
    8
    SHARED DISPOSITIVE POWER
     
     
    5,749,432
     
     
     
     
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
     5,749,432
     
     
     
     
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
     
    ☐
     
     
     
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
     
     19.3
     
     
     
     
    12
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
     PN
     
     
     
     
     

    Item 1(a). Name of Issuer:

     AN2 Therapeutics, Inc.
     
    Item 1(b). Address of Issuer's Principal Executive Offices:

     1800 El Camino Real, Suite D, Menlo Park, California 94027

    Item 2(a). Name of Person Filing:

     BML Investment Partners, L.P.

    Item 2(b). Address of Principal Business Office or, if none, Residence:

     65 E Cedar, Suite 2, Zionsville, IN 46077

    Item 2(c). Citizenship:

     Delaware

    Item 2(d). Title of Class of Securities:

     Common Stock, $0.00001 par value per share
     
    Item 2(e). CUSIP Number:

     037326105


    Item 3. If This Statement Is Filed Pursuant to Sections 240.13d-1(b) or
    240.13d-2(b) or (c), Check Whether the Person Filing Is a(n):


    (a) ☐ Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o);


    (b) ☐ Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c);


    (c) ☐ Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c);


    (d) ☐ Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);


    (e) ☐ Investment adviser in accordance with Section 240.13d-1(b)(1)(ii)(E);


    (f) ☐ Employee benefit plan or endowment fund in accordance with Section 240.13d-1(b)(1)(ii)(F);


    (g) ☐ Parent holding company or control person in accordance with Section 240.13d-1(b)(1)(ii)(G);


    (h) ☐ Savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);


    (i) ☐ Church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);


    (j) ☐ A non-U.S. institution in accordance with Section 240.13d-1(b)(1)(ii)(J);


    (k) ☐ Group, in accordance with Section 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Section 240.13d-1(b)(1)(ii)(J), please specify the type of institution: ____________________________ .
     
    Item 4. Ownership.


    (a) Amount beneficially owned:5,749,432


    (b) Percent of class: 19.3


    (c) Number of shares as to which the person has:


    (i) Sole power to vote or to direct the vote: 0


    (ii) Shared power to vote or to direct the vote: 5,749,432

      (iii) Sole power to dispose or to direct the disposition of: 0

      (iv) Shared power to dispose or to direct the disposition of: 5,749,432
     


    Item 5. Ownership of Five Percent or Less of a Class.

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☐.

    Item 6. Ownership of More Than Five Percent on Behalf of Another Person.

    n/a
     
    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.

     n/a

    Item 8. Identification and Classification of Members of the Group.

     n/a

    Item 9. Notice of Dissolution of Group.

     n/a
     
    Item 10.
    Certification.
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.
     


    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Dated: August 14, 2024
     
     
    COMPANY NAME
     
     
    By:
     /s/ Braden M Leonard
       
    Name:  Braden M Leonard
       
    Title:  Managing Member
     
    BML Investment Partners, L.P. is a Delaware limited partnership whose sole general partner is BML Capital Management, LLC. The managing member of BML Capital Management, LLC is Braden M. Leonard. As a result, Braden M. Leonard is deemed to be the indirect owner of the shares held directly by BML Investment Partners, L.P. Despite such shared beneficial ownership, the reporting persons disclaim that they constitute a statutory group within the meaning of Rule 13d-5(b)(1) of the Exchange Act.
     

    Get the next $ANTX alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $ANTX

    DatePrice TargetRatingAnalyst
    8/9/2024In-line → Underperform
    Evercore ISI
    8/9/2024$5.00 → $1.00Outperform → Market Perform
    Leerink Partners
    7/3/2024$5.00Market Perform → Outperform
    Leerink Partners
    4/2/2024$6.00Mkt Perform → Mkt Outperform
    JMP Securities
    2/13/2024$23.00 → $7.00Outperform → Market Perform
    Leerink Partners
    2/12/2024$25.00 → $7.00Outperform → In-line
    Evercore ISI
    2/12/2024Outperform → Perform
    Oppenheimer
    2/12/2024Mkt Outperform → Mkt Perform
    JMP Securities
    More analyst ratings

    $ANTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Aziz Kabeer was granted 11,875 shares, increasing direct ownership by 64% to 30,552 units (SEC Form 4)

      4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)

      7/11/25 6:23:23 PM ET
      $ANTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Marks Gilbert Lynn was granted 11,875 shares, increasing direct ownership by 29% to 53,382 units (SEC Form 4)

      4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)

      7/11/25 6:20:48 PM ET
      $ANTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Martin Patricia A. was granted 3,750 shares, increasing direct ownership by 60% to 9,981 units (SEC Form 4)

      4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)

      7/11/25 6:17:36 PM ET
      $ANTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ANTX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • AN2 Therapeutics Reports Key Insights from 200-Patient Observational Study in Acute Melioidosis, Laying Groundwork for Phase 2 Proof-of-Concept Trial of Epetraborole

      Study highlights high mortality despite standard of care and provides critical data to optimize design for upcoming proof-of-concept trial for epetraborole Observational Study funded by the National Institutes of Health AN2 Therapeutics, Inc. (NASDAQ:ANTX), a clinical-stage biopharmaceutical company developing novel small molecule therapeutics derived from its boron chemistry platform, today announced the completion of a 200-patient observational study in acute melioidosis, a highly lethal bacterial infection and recognized biothreat. The study, conducted under real-world conditions in acute hospital settings, evaluated patients receiving the current standard of care (SoC): IV meropenem

      6/30/25 7:00:00 AM ET
      $ANTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • AN2 Therapeutics Announces Poster Presentation Highlighting M. Abscessus Data at 2025 Colorado Mycobacteria Conference

      Epetraborole's potent activity against M. abscessus supports further investigation as a potential therapy for disease with an estimated all-cause mortality of 45% AN2 Therapeutics, Inc. (NASDAQ:ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, today announced that the company will present a poster highlighting the preclinical activity of epetraborole against M. abscessus on Thursday, May 29, 2025 at the Nontuberculous Mycobacteria Conference to be held May 27-30, 2025 at Colorado State University. It is estimated that M. abscessus affects approximately 50,000 patients in the U.S., Japan and

      5/29/25 7:00:00 AM ET
      $ANTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • AN2 Therapeutics Reports Data from the Phase 3 Portion of Previously Terminated EBO-301 Study and Outlines Future Milestones from Boron Chemistry Pipeline

      EBO-301 truncated Phase 3 study (n=97) misses primary endpoint; results unable to confirm clinical efficacy observed in Phase 2 study, patients had underlying severe, advanced MAC lung disease Extensive enabling NTM data provides potential path forward in M. abscessus lung disease Company focus remains centered on boron chemistry pipeline with initiation of high impact clinical programs in infectious diseases and an emerging oncology portfolio Initiated start up activities for Phase 1 first in human study in healthy volunteers of AN2-502998, under development to treat chronic Chagas disease Topline data for standard-of-care melioidosis observational trial expected in 2Q25; Phase 2 study

      5/1/25 4:00:00 PM ET
      $ANTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ANTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • AN2 Therapeutics downgraded by Evercore ISI

      Evercore ISI downgraded AN2 Therapeutics from In-line to Underperform

      8/9/24 8:39:40 AM ET
      $ANTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • AN2 Therapeutics downgraded by Leerink Partners with a new price target

      Leerink Partners downgraded AN2 Therapeutics from Outperform to Market Perform and set a new price target of $1.00 from $5.00 previously

      8/9/24 7:16:36 AM ET
      $ANTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • AN2 Therapeutics upgraded by Leerink Partners with a new price target

      Leerink Partners upgraded AN2 Therapeutics from Market Perform to Outperform and set a new price target of $5.00

      7/3/24 7:25:34 AM ET
      $ANTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ANTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by AN2 Therapeutics Inc.

      SC 13G/A - AN2 Therapeutics, Inc. (0001880438) (Subject)

      11/14/24 4:29:18 PM ET
      $ANTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by AN2 Therapeutics Inc.

      SC 13G/A - AN2 Therapeutics, Inc. (0001880438) (Subject)

      11/14/24 4:16:45 PM ET
      $ANTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by AN2 Therapeutics Inc.

      SC 13G/A - AN2 Therapeutics, Inc. (0001880438) (Subject)

      11/13/24 4:25:27 PM ET
      $ANTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ANTX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Executive Officer Easom Eric bought $10,665 worth of shares (10,000 units at $1.07), increasing direct ownership by 4% to 256,380 units (SEC Form 4)

      4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)

      6/3/25 4:46:15 PM ET
      $ANTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Fitzpatrick Margaret M bought $10,133 worth of shares (8,610 units at $1.18) (SEC Form 4)

      4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)

      5/29/25 4:17:48 PM ET
      $ANTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Readnour Robin Shane bought $86,708 worth of shares (60,000 units at $1.45) (SEC Form 4)

      4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)

      12/10/24 8:46:19 PM ET
      $ANTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ANTX
    SEC Filings

    See more
    • SEC Form 8-K filed by AN2 Therapeutics Inc.

      8-K - AN2 Therapeutics, Inc. (0001880438) (Filer)

      6/20/25 7:00:37 AM ET
      $ANTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13D/A filed by AN2 Therapeutics Inc.

      SCHEDULE 13D/A - AN2 Therapeutics, Inc. (0001880438) (Subject)

      6/18/25 11:08:01 AM ET
      $ANTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • AN2 Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure

      8-K - AN2 Therapeutics, Inc. (0001880438) (Filer)

      6/11/25 7:30:25 AM ET
      $ANTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ANTX
    Financials

    Live finance-specific insights

    See more
    • AN2 Therapeutics Adopts Limited Duration Stockholder Rights Plan

      AN2 Therapeutics, Inc. (NASDAQ:ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, today announced that it has adopted a limited duration stockholder rights plan, which is scheduled to expire on August 15, 2025. The Company recently became aware of the rapid accumulation of a significant amount (19.3%) of the common stock of the Company by BML Investment Partners, L.P. (BML), as disclosed in a Schedule 13G/A filed with the U.S. Securities and Exchange Commission (SEC) on August 14, 2024. The Board of Directors believes that the rights plan will help promote the fair and equal treatment of all

      8/16/24 7:00:00 AM ET
      $ANTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • AN2 Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business and Scientific Highlights

      Phase 2/3 trial (EBO-301) in treatment-refractory Mycobacterium avium Complex (TR-MAC) continues with Phase 2 topline results expected in summer 2024 and Phase 3 enrollment pause in place during continued analysis of incoming data; plan to discuss with FDA Cash, cash equivalents, and investments of $134.5 million at December 31, 2023 AN2 Therapeutics, Inc. (NASDAQ:ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today reported financial results for the fourth quarter and year ended December 31, 2023. "AN2's cash position remains strong as we advance our innovative boron-based pi

      3/28/24 4:10:00 PM ET
      $ANTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Brii Biosciences Provides Corporate Update and Reports Full-Year 2023 Financial Results

      Transitioning HBV cure programs into multiple late-stage combination studies with interim results throughout 2024 and 2025 informing Company's registrational strategy Integrating R&D, manufacturing and commercial upsides by acquiring full intellectual property rights of BRII-179 and expanding its manufacturing footprint Prioritizing company resources with a robust cash balance of US$376 million supporting operations until 2027 Company to host a conference call (English session) on March 25 at 8:30 AM ET / 8:30 PM HKT DURHAM, N.C. and BEIJING, March 22, 2024 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio" or the "Company", stock code: 2137.HK), a biotechnology company developing therapie

      3/22/24 7:00:00 AM ET
      $ANTX
      $VBIV
      $VIR
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)

    $ANTX
    Leadership Updates

    Live Leadership Updates

    See more
    • Brii Biosciences Provides Latest Clinical Development and Corporate Updates

      Company extends BRII-179 license to global rights and introduces preventive vaccine, PreHevbri® in Greater China and Asia Pacific markets New data from BRII-835 + PEG-IFN-α study have demonstrated that robust anti-HBs antibody responses at the end of treatment are associated with sustained HBsAg loss 24 weeks post treatment Company owns exclusive global rights of BRII-693 in development for difficult-to-treat carbapenem-resistant Gram-negative bacterial infections Dr. David Margolis appointed as Chief Medical Officer to lead organization's late-stage clinical programs towards commercialization DURHAM, N.C. and BEIJING, July 5, 2023 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio" or the

      7/5/23 7:18:00 PM ET
      $ANTX
      $VBIV
      $VIR
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • AN2 Therapeutics Appoints Maggie FitzPatrick to Its Board of Directors

      AN2 Therapeutics, Inc., (NASDAQ:ANTX) a clinical-stage biopharmaceutical company developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today announced the appointment of Maggie FitzPatrick to its Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220509005229/en/Maggie FitzPatrick, Board of Directors, AN2 Therapeutics, Inc. (Photo: Business Wire) Maggie FitzPatrick is a highly accomplished corporate affairs executive who has led global communications and public affairs at leading healthcare companies, including Johnson & Johnson and Cigna. "As a recognized leader in the a

      5/9/22 7:00:00 AM ET
      $ANTX
      Biotechnology: Pharmaceutical Preparations
      Health Care